Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NPR3 | P17342 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12193562 | 1.00 | ITGB3 (0.47) | ITGB3ITGA2BCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL12193561 | 0.86 | MAPT (0.49) | ITGB3ITGA2BCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL8250813 | 0.86 | MAPT (0.49) | ITGB3ITGA2BCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL12341873 | 0.86 | F2 (0.45) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL4733396 | 0.84 | KLK5 (0.41) | ITGB3ITGA2BMAPTTDP1CTSL | |
| SCHEMBL7347913 | 0.84 | F2 (0.55) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL12341800 | 0.84 | F2 (0.55) | ITGB3ITGA2BCTSLCTSBCTSS | |
| SCHEMBL19485480 | 0.81 | CTSK (0.62) | ITGB3ITGA2BMAPTTDP1POLB | |
| SCHEMBL9219338 | 0.81 | CTSK (0.62) | ITGB3ITGA2BMAPTTDP1POLB | |
| SCHEMBL12317089 | 0.81 | CA12 (0.44) | CYP3A4CYP2C8CYP2C9NPR3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268935-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8030328-B2 | Imidazolone phenylalanine derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20070037804-A1 | Imidazolone phenylalanine derivatives | TBD | 2007-02-15 | — | — | US | disclosed |
| US-20070021555-A1 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006127584-A1 | IMIDAZOLONE PHENYLALANINE DERIVATIVES AS VLA-4 ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037804-A1 | Imidazolone phenylalanine derivatives | VCAM1, ICAM1, IL4I1 | ITGB3 55/4885ITGA2B 222/4885CYP3A4 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.